Enhancing health and comfort through innovative pain management

Education Hub

Resources

01 · Article

An Evidence-Based Assessment of Local Anesthetic Allergy Risk and Clinical Safety

ENDURA-KT is a preservative-free combination of 0.2% tetracaine, 0.4% lidocaine and 1:250,000 epinephrine. Tetracaine, an ester local anesthetic, has been used in medicine since the 1930s and lidocaine an amide, has been in use since 1948. The combination of these drugs is not new. Since 1994, “LET” gel containing 0.5% tetracaine, 4% lidocaine, and 1:1000 epinephrine has been widely utilized to anesthetize lacerations in a pediatric ER setting prior to wound closure. LET is also a cGMP compounded product. Pliaglis Cream, an FDA-approved combination containing 7% lidocaine and 7% tetracaine, is a topical preparation designed to produce cutaneous anesthesia prior to dermatologic procedures.

02 · FDA-registered cGMP facility

For more information

FDA: Compounding and the FDA, Questions and Answers: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers

FDA: Information for Outsourcing Facilities: https://www.fda.gov/drugs/human-drug-compounding/information-outsourcing-facilities

FDA: Human Drug Compounding Laws: https://www.fda.gov/drugs/human-drug-compounding/human-drug-compounding-laws

FDA: Promotion of Compounded Drugs: https://www.fda.gov/drugs/human-drug-compounding/fda-telehealth-companies-what-know-when-promoting-compounded-drugs

OurPharma: Company and Facility: https://ourpharma.net/company/

OurPharma: Quality FAQs and Contact: https://ourpharma.net/contact-us/

Ready to take the next step?

Have questions about Endura-KT? Explore the details or connect with our team to learn more.